XML 83 R71.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders’ Equity (Deficit) - Schedule of Warrants and Rights Activity (Details)
Dec. 31, 2024
$ / shares
shares
Schedule of Warrants and Rights Activity [Line Items]  
Warrants/Options Outstanding (in Shares) | shares 5,363,884
Weighted Average Exercise Price (in Dollars per share) | $ / shares $ 120.93
Average Remaining Contractual Life (Years) 2 years 11 months 26 days
March 24, 2023 [Member]  
Schedule of Warrants and Rights Activity [Line Items]  
Issue date Mar. 04, 2023
Period ended Dec. 31, 2024
Contractual life (years) 2 years
Warrants/Options Outstanding (in Shares) | shares 1,263,000
Weighted Average Exercise Price (in Dollars per share) | $ / shares $ 10
Average Remaining Contractual Life (Years) 2 months 1 day
October 23, 2023 [Member]  
Schedule of Warrants and Rights Activity [Line Items]  
Issue date Oct. 23, 2023
Period ended Dec. 31, 2024
Contractual life (years) 5 years
Warrants/Options Outstanding (in Shares) | shares 1,700,884
Weighted Average Exercise Price (in Dollars per share) | $ / shares $ 371.9
Average Remaining Contractual Life (Years) 3 years 9 months 21 days
November 21, 2023 [Member]  
Schedule of Warrants and Rights Activity [Line Items]  
Issue date Nov. 21, 2023 [1]
Period ended Dec. 31, 2024 [1]
Contractual life (years) 5 years [1]
Warrants/Options Outstanding (in Shares) | shares 2,400,000 [1]
Weighted Average Exercise Price (in Dollars per share) | $ / shares $ 1.44 [1]
Average Remaining Contractual Life (Years) 3 years 10 months 20 days [1]
[1] In accordance with the anti-dilution provisions of the Follow-On Warrants, the per share exercise price was reduced from $3.90 to $1.44, while the number of shares issuable was increased to approximately 8,333,336, thereby maintaining the aggregate exercise price. This adjustment was reflected in the Company’s filing on February 27, 2025.